Kiniksa Pharmaceuticals International

Kiniksa is a biopharmaceutical company that focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients with unmet medical needs. Its main commercial product is ARCALYST (rilonacept), which treats recurrent pericarditis. Its pipeline includes KPL-387 for recurrent pericarditis and vixarelimab for prurigo nodularis.